SLC5A2 and diabetic kidney disease: This also includes diabetic nephropathy [40], the primary cause of CKD in developed countries, even though several drugs, such as sodium glucose cotransporter 2 inhibitor (SGLT2i), glucagon-like peptide 1 receptor agonist (GLP-1 RA) or angiotensin II receptor blockers (ARB), were found to reduce the risk of kidney failure [40, 41].